<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00919503</url>
  </required_header>
  <id_info>
    <org_study_id>2256.00</org_study_id>
    <secondary_id>NCI-2010-01277</secondary_id>
    <secondary_id>2256.00</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT00919503</nct_id>
  </id_info>
  <brief_title>Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders</brief_title>
  <official_title>Allogeneic Hematopoietic Cell Transplantation for Patients With Nonmalignant Inherited Disorders Using a Treosulfan Based Preparative Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II clinical trial studies how well treosulfan and fludarabine phosphate with or
      without low dose radiation before donor stem cell transplantation works in treating patients
      with nonmalignant (noncancerous) diseases. Hematopoietic cell transplantation has been shown
      to be curative for many patients with nonmalignant (noncancerous) diseases such as primary
      immunodeficiency disorders, bone marrow failure syndromes, hemoglobinopathies, and inborn
      errors of metabolism (metabolic disorders). Powerful chemotherapy drugs and/or radiation are
      often used to condition the patient before infusion of the new healthy donor cells. The
      purpose of the conditioning therapy is to destroy the patient's abnormal bone marrow which
      doesn't work properly in order to make way for the new healthy donor cells which functions
      normally. Although effective in curing the patient's disease, many hematopoietic cell
      transplantation regimens use intensive chemotherapy and/or radiation which can be quite
      toxic, have significant side effects, and can potentially be life-threatening. Investigators
      are investigating whether a new conditioning regimen that uses less intensive drugs
      (treosulfan and fludarabine phosphate) with or without low dose radiation results in new
      blood-forming cells (engraftment) of the new donor cells without increased toxicities in
      patients with nonmalignant (noncancerous) diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate, within the limits of a phase II study, the preliminary efficacy as defined by
      engraftment, of a regimen consisting of treosulfan and fludarabine (fludarabine phosphate)
      followed by allogeneic hematopoietic cell transplant (HCT) in patients with nonmalignant
      inherited disorders.

      SECONDARY OBJECTIVES:

      I. To evaluate the incidence of non-relapse mortality 200 days and 1 year post-HCT.

      II. To evaluate the incidence of grade II-IV acute graft-versus-host disease (GVHD).

      III. To evaluate the incidence of chronic GVHD as defined as those patients requiring
      systemic immunosuppression.

      IV. To evaluate donor chimerism on days +28 and +100.

      V. To assess disease response following HCT.

      VI. To evaluate immune reconstitution following HCT.

      VII. To evaluate the incidence of infections.

      VIII. To evaluate overall survival.

      OUTLINE:

      CONDITIONING REGIMEN: Patients receive treosulfan intravenously (IV) over 2 hours on days -6
      to -4 and fludarabine phosphate IV over 1 hour on days -6 to -2. Patients receive
      anti-thymocyte globulin IV over 4-6 hours on days -4 to -2. Patients undergoing umbilical
      cord blood transplantation will also receive low dose total-body irradiation on day -1.

      TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or
      umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or
      umbilical cord blood will depend on the donor status.

      IMMUNOSUPPRESSION: Patients receive a combination of immunosuppressive medications to try and
      prevent graft-versus-host disease. If patients undergo bone marrow or PBSC transplantation,
      tacrolimus and methotrexate will be used. If patients undergo cord blood transplantation,
      cyclosporine and mycophenolate mofetil will be used. In general, patients will receive
      immunosuppression until at least 180 days after transplantation; however they could be on
      immunosuppression longer if they develop graft versus host disease.

      After completion of study treatment, patients are followed up periodically for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2009</start_date>
  <primary_completion_date type="Anticipated">February 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preliminary efficacy</measure>
    <time_frame>1 year following transplant</time_frame>
    <description>Defined by engraftment of a regimen consisting of treosulfan and fludarabine phosphate followed by allogeneic hematopoietic cell transplantation in patients with nonmalignant inherited disorders.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>Up to 1 year following transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade II-IV acute graft-versus-host disease</measure>
    <time_frame>Within the first year following transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic graft-versus-host disease</measure>
    <time_frame>Within the two years (on average) following transplant</time_frame>
    <description>Defined as those patients requiring systemic immunosuppression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor chimerism</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Peripheral blood chimerism for CD3, CD33, CD19, and CD56 will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease response following hematopoietic cell transplantation</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution following hematopoietic cell transplantation</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Measured using samples of peripheral blood, and bone marrow aspirate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections</measure>
    <time_frame>Within the first year following transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Within the two years following transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hematopoietic Cell Transplantation Recipient</condition>
  <condition>Non-Malignant</condition>
  <arm_group>
    <arm_group_label>Group I (PBSCT and BMT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description. Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (UBCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description. Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
    <description>Infused IV</description>
    <arm_group_label>Group I (PBSCT and BMT)</arm_group_label>
    <other_name>Allo BMT</other_name>
    <other_name>Allogeneic BMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (PBSCT and BMT)</arm_group_label>
    <arm_group_label>Group II (UBCT)</arm_group_label>
    <other_name>Antithymocyte Globulin</other_name>
    <other_name>Antithymocyte Serum</other_name>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>ATS</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Group II (UBCT)</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>Ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Gengraf</other_name>
    <other_name>Neoral</other_name>
    <other_name>OL 27-400</other_name>
    <other_name>Sandimmun</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>SangCya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (PBSCT and BMT)</arm_group_label>
    <arm_group_label>Group II (UBCT)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group I (PBSCT and BMT)</arm_group_label>
    <arm_group_label>Group II (UBCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (PBSCT and BMT)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Group II (UBCT)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Infused IV</description>
    <arm_group_label>Group I (PBSCT and BMT)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Group I (PBSCT and BMT)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo total body irradiation</description>
    <arm_group_label>Group II (UBCT)</arm_group_label>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (PBSCT and BMT)</arm_group_label>
    <arm_group_label>Group II (UBCT)</arm_group_label>
    <other_name>1,2,3, 4-Butanetetrol, 1,4-dimethanesulfonate, [R-(R*,S*)]-</other_name>
    <other_name>Dihydroxybusulfan</other_name>
    <other_name>Ovastat</other_name>
    <other_name>Treosulphan</other_name>
    <other_name>Tresulfon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Umbilical Cord Blood Transplantation</intervention_name>
    <description>Single or double unit umbilical cord blood transplant, infused IV</description>
    <arm_group_label>Group II (UBCT)</arm_group_label>
    <other_name>Cord Blood Transplantation</other_name>
    <other_name>UCB transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a nonmalignant disease treatable by allogeneic HCT

          -  Patients with a known nonmalignant disease that is not clearly defined will need to be
             discussed with the protocol principal investigator (PI) (Dr. Lauri Burroughs) and
             potentially the nonmalignant board to determine if they are eligible for HCT on this
             study

          -  DONOR: Human leukocyte antigens (HLA)-identical related donors or unrelated donors
             matched for HLA-A, B, C, DRB1, and DQB1 or mismatched for a single allele at HLA-A, B,
             C, DRB1 or a single DQB1 antigen or allele mismatch by high resolution
             deoxyribonucleic acid (DNA) typing

          -  DONOR: PBSC is the preferred cell source (when feasible) for fully matched donors;
             PBSC may also be used for a mismatched donor following discussion with the PI; bone
             marrow is allowed when PBSC is not feasible or as determined by the PI

          -  DONOR: HLA-matched sibling bone marrow in combination with HLA-matched sibling
             umbilical cord blood if the HLA-matched sibling umbilical cord blood was collected and
             stored; the HLA-matched sibling bone marrow and cord blood would be matched for HLA-A,
             B, C, DRB1, and DQB1

          -  DONOR: Unrelated Umbilical Cord Blood: Unit selection is based on the cryopreserved
             total nucleated cell (TNC) dose and matching at HLA-A, B antigen level and DRB1 allele
             level typing; while HLA-C antigen/allele level typing is not considered in the
             matching criteria, if available, may be used to optimize unit selection

          -  DONOR: Unrelated Umbilical Cord Blood: The patient and the cord blood unit(s) must be
             matched for at least 4 of 6 loci as defined above

          -  DONOR: Unrelated Umbilical Cord Blood: Selection of two umbilical cord blood (UCB)
             units is allowed to provide sufficient cell dose

          -  DONOR: Unrelated Umbilical Cord Blood: The UCB unit with the least HLA disparity (with
             the patient) will be selected first (i.e., selection priority is 6/6 match &gt; 5/6
             match&gt; 4/6 match); additional UCB units then may be selected to achieve the required
             cell dose; if a second unit is required, this unit will be the unit that most closely
             HLA matches the patient and meets minimum size criteria outlined below of at least 1.5
             x 10^7 TNC/kg (ie a smaller more closely matched unit will be selected over a larger
             less well matched unit as long as minimum criteria are met)

          -  DONOR: Unrelated Umbilical Cord Blood: Each UCB unit MUST contain at least 1.5 x 10^7
             TNC per kilogram recipient weight

          -  DONOR: Unrelated Umbilical Cord Blood: The total cell dose of the combined units must
             be at least 3.0 x 10^7 TNC per kilogram recipient weight

        Exclusion Criteria:

          -  Patients with idiopathic aplastic anemia and Fanconi anemia; (patients with aplastic
             anemia associated with paroxysmal nocturnal hemoglobinuria [PNH] or inherited marrow
             failure syndromes, except Fanconi anemia, will be allowed)

          -  Patients with impaired cardiac function as evidenced by ejection fraction &lt; 35% (or,
             if unable to obtain ejection fraction, shortening fraction of &lt; 26%) or cardiac
             insufficiency requiring treatment or symptomatic coronary artery disease; patients
             with a shortening fraction &lt; 26% may be enrolled if approved by a cardiologist

          -  Patients with impaired pulmonary function as evidenced by diffusion capacity of the
             lung for carbon monoxide (DLCO) &lt; 50% of predicted (or, if unable to perform pulmonary
             function tests, then oxygen [O2] saturation &lt; 92% on room air)

          -  Patients with impaired renal function as evidenced by creatinine-clearance &lt; 50% for
             age, weight, height or serum creatinine &gt; 2 x upper normal limit or dialysis-dependent

          -  Patients with evidence of synthetic dysfunction or severe cirrhosis requiring deferral
             of conditioning as recommended by a gastroenterology specialist

          -  Patients with an active infectious disease requiring deferral of conditioning; as
             recommended by an infectious disease specialist

          -  Patients who are positive for human immunodeficiency virus (HIV)

          -  Females who are pregnant or breast-feeding

          -  Patients with a known hypersensitivity to treosulfan and/or fludarabine

          -  Receiving another experimental drug within 4 weeks of initiation of conditioning (day
             -6) unless approved by the PI

          -  DONOR: Deemed unable to undergo marrow harvesting or PBSC mobilization and
             leukapheresis

          -  DONOR: HIV-positive

          -  DONOR: With active infectious hepatitis

          -  DONOR: Females with a positive pregnancy test

          -  DONOR: HLA-matched sibling cord blood exclusions: Any cord blood units without full
             maternal testing and negative results for hepatitis A, B, C, HIV, and HTLV-1 viruses;
             any additional available virology results on the unit itself will be reviewed but are
             not mandated, complete or always available; cord blood units are presumed to be
             cytomegalovirus (CMV) negative regardless of serologic testing due to passive
             transmission of maternal CMV antibodies

          -  DONOR: Unrelated Umbilical Cord Blood: Any cord blood units with &lt; 1.5 x 10^7 total
             nucleated cells per kilogram recipient weight

          -  DONOR: Unrelated Umbilical Cord Blood: Any cord blood units without full maternal
             testing and negative results for hepatitis A, B, C, HIV, and HTLV-1 viruses; any
             additional available virology results on the unit itself will be reviewed but are not
             mandated, complete or always available; cord blood units are presumed to be CMV
             negative regardless of serologic testing due to passive transmission of maternal CMV
             antibodies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauri Burroughs</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauri M. Burroughs</last_name>
      <phone>206-667-2396</phone>
      <email>lburroug@fhcrc.org</email>
    </contact>
    <investigator>
      <last_name>Lauri M. Burroughs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauri M. Burroughs</last_name>
      <phone>206-667-2396</phone>
      <email>lburroug@fhcrc.org</email>
    </contact>
    <investigator>
      <last_name>Lauri M. Burroughs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2009</study_first_submitted>
  <study_first_submitted_qc>June 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2009</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nonmalignant diseases</keyword>
  <keyword>nonmalignant inherited disorders</keyword>
  <keyword>primary immunodeficiency diseases</keyword>
  <keyword>primary immune deficiency disorders</keyword>
  <keyword>chronic granulomatous</keyword>
  <keyword>disease</keyword>
  <keyword>IPEX syndrome</keyword>
  <keyword>hemophagocytic lymphohistiocytosis</keyword>
  <keyword>Wiskott Aldrich Syndrome</keyword>
  <keyword>bone marrow failure syndromes</keyword>
  <keyword>Shwachman Diamond Syndrome</keyword>
  <keyword>Dyskeratosis Congenita</keyword>
  <keyword>Diamond Blackfan Anemia</keyword>
  <keyword>inborn errors of metabolism</keyword>
  <keyword>metabolic diseases</keyword>
  <keyword>hemoglobinopathies</keyword>
  <keyword>sickle cell disease</keyword>
  <keyword>thalassemia</keyword>
  <keyword>reduced intensity transplantation</keyword>
  <keyword>hematopoietic cell transplantation</keyword>
  <keyword>bone marrow transplantation</keyword>
  <keyword>umbilical cord blood transplantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Treosulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

